Epix Delaware, Inc.

Other

Cytopathfinder, Inc.

Galenea Corp.

Merav Fichman

Yael Marantz

Sharon Shacham

Oren Becker

Srinivasa Rao Cheruku

Dale S Dhanoa

Anurag Sharadendu

Silvia Noiman

Dongli Chen

Pradyumna Mohanty

Boaz Inbal

Alexander Heifetz

Shay Bar-Haim

Raphael Nudelman

Ashis K Saha

Mercedes Lobera

Hanoch Senderowitz

Pini Orbach

Rosa Melendez

Shomir Ghosh

Jian Lin

Xiang Y Yu

Zhaoda Zhang

Steffi Koerner

Laurence Wu

Efrat Ben-Zeev

Laurence I Wu

Sharon Shachem

Rosa E Melendez

The invention relates to 5-HTreceptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and type II diabetes; and psychological disorders such as schizophrenia, are disclosed.

Substituted arylamine compounds and methods of treatment

Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein. 

Carboxamide compounds and their use

The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Arylpiperazinyl compounds

The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formulae I: and II, and synthesis and uses of those compounds for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Growing community of inventors

Modiin, Israel

Merav Fichman